Overview

Study to Evaluate the Safety and Efficacy of MEM 3454 as Adjunctive Treatment in Combination With a Preexisting Antipsychotic in Patients With Cognitive Impairment Associated With Schizophrenia

Status:
Unknown status

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

To establish the proof of concept that MEM 3454, used as add-on pharmacotherapy, is a safe and effective treatment in patients with cognitive impairment associated with schizophrenia (CIAS).

Phase:

Phase 2

Details

Lead Sponsor:

Memory Pharmaceuticals

Treatments:

Antipsychotic Agents